HCA Healthcare (NYSE:HCA) Given New $561.00 Price Target at TD Cowen

HCA Healthcare (NYSE:HCA) had its target price upped by TD Cowen from $529.00 to $561.00 in a report released on Tuesday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also recently commented on HCA. Oppenheimer increased their price target on HCA Healthcare from $500.00 to $540.00 and gave the company an “outperform” rating in a report on Wednesday, January 28th. Royal Bank Of Canada raised their target price on HCA Healthcare from $525.00 to $555.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 28th. Robert W. Baird boosted their price target on shares of HCA Healthcare from $423.00 to $450.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Wall Street Zen cut shares of HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Finally, JPMorgan Chase & Co. increased their price target on shares of HCA Healthcare from $420.00 to $535.00 and gave the company a “neutral” rating in a research note on Friday, February 20th. Sixteen analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $537.73.

HCA Healthcare Stock Down 1.3%

Shares of NYSE HCA opened at $537.78 on Tuesday. The stock has a market capitalization of $120.26 billion, a price-to-earnings ratio of 18.95, a price-to-earnings-growth ratio of 1.67 and a beta of 1.34. HCA Healthcare has a 52 week low of $310.18 and a 52 week high of $552.90. The firm has a 50-day simple moving average of $503.07 and a 200-day simple moving average of $467.72.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Tuesday, January 27th. The company reported $8.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.37 by $0.64. HCA Healthcare had a net margin of 8.97% and a negative return on equity of 409.11%. The company had revenue of $19.51 billion during the quarter, compared to analysts’ expectations of $19.67 billion. During the same quarter in the prior year, the company earned $6.22 EPS. HCA Healthcare’s revenue was up 6.7% compared to the same quarter last year. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, equities research analysts expect that HCA Healthcare will post 24.98 EPS for the current year.

HCA Healthcare Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 17th will be paid a dividend of $0.78 per share. This represents a $3.12 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Tuesday, March 17th. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.72. HCA Healthcare’s dividend payout ratio is currently 10.99%.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, SVP Christopher F. Wyatt sold 4,000 shares of the business’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $505.00, for a total transaction of $2,020,000.00. Following the sale, the senior vice president directly owned 44,379 shares in the company, valued at $22,411,395. This represents a 8.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael S. Cuffe sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $498.09, for a total transaction of $747,135.00. Following the completion of the transaction, the executive vice president directly owned 30,003 shares of the company’s stock, valued at approximately $14,944,194.27. The trade was a 4.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 15,214 shares of company stock valued at $7,797,595. 1.30% of the stock is owned by insiders.

Institutional Investors Weigh In On HCA Healthcare

Hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC acquired a new position in shares of HCA Healthcare during the fourth quarter worth about $1,021,000. NewEdge Advisors LLC grew its holdings in HCA Healthcare by 11.9% during the 1st quarter. NewEdge Advisors LLC now owns 3,859 shares of the company’s stock worth $1,334,000 after acquiring an additional 409 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in shares of HCA Healthcare by 5.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 630 shares of the company’s stock valued at $241,000 after purchasing an additional 33 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new position in shares of HCA Healthcare during the second quarter worth $48,000. Finally, Savant Capital LLC raised its stake in HCA Healthcare by 15.5% in the second quarter. Savant Capital LLC now owns 3,302 shares of the company’s stock valued at $1,265,000 after buying an additional 444 shares in the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

More HCA Healthcare News

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: TD Cowen raised its price target on HCA to $561 and kept a Buy rating, signaling continued analyst confidence and suggesting upside versus the current share level. This type of analyst action often supports buying interest. Article Title
• Positive Sentiment: HCA system was cleared to build a freestanding emergency room despite community pushback — a win for local expansion plans and potential incremental revenue/volume growth in the market where it will operate. Article Title
• Positive Sentiment: Zacks published pieces highlighting HCA as a momentum and value stock and as a name with earnings growth/price strength — favorable retail/quant narratives that can attract buyers. (Multiple Zacks items.) Momentum Article
• Neutral Sentiment: Management presented at the Barclays 28th Annual Global Healthcare Conference — transcripts provide detail on strategy, capital allocation and growth initiatives but offered no headline surprises that would immediately re-rate the stock. Barclays Transcript
• Neutral Sentiment: HCA also presented at the Leerink Global Healthcare Conference — additional management commentary (transcript) that reinforces the same operational and growth themes but adds incremental detail rather than new catalysts. Leerink Transcript
• Neutral Sentiment: HCA’s CIO discussed the importance of “operational quiet” for digital transformation — an execution-focused piece that underlines IT/digital investment discipline but is more about long-term efficiency than an immediate earnings shock. CIO Article

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.